IDM Pharma, Inc. (IDMI) Announces Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
IDM Pharma, Inc. announced that the European Commission has formally authorized MEPACT® (mifamurtide, L-MTP-PE) for the treatment of patients with…